GlassScriptPhysician profile
Douglas Curran
NPI 1821093824
$952.19
in general payments reported to CMS, 2019-2025
13 companies · $23.69 in 2025
The $23.69 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $139 · 2021: $95.89 · 2022: $17.50 · 2023: $66.75 · 2024: $286 · 2025: $23.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $376.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $264.77 | 2023-2024 | |
| Amgen INC. | $195.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $135.62 | 2020-2025 | Breztri |
| Abbvie INC. | $67.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.29 | 2019 | |
| Novo Nordisk INC | $45.00 | 2020-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $41.58 | 2019 | |
| Mylan Specialty L.P. | $36.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.76 | 2019 | |
| Hologic Sales and Service, LLC | $26.97 | 2024 | Aptima |
| Xeris Pharmaceuticals, INC. | $24.91 | 2023 | Keveyis |
| Kci USA, INC. | $18.18 | 2023 | 3m Cavilon, Activ.A.C., V.A.C. Dermatac |
| E.R. Squibb & Sons, L.L.C. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Curran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.